New findings show Zenkuda surpasses sham treatment in efficacy.
- Zenkuda shows improvement over sham treatment
- Phase 3 study demonstrates significant findings
- Potential advancement in diabetic retinopathy care
Kodiak Sciences has announced positive topline results from its GLOW2 study, the second Phase 3 trial evaluating Zenkuda (tarcocimab tedromer) for patients with diabetic retinopathy. The study indicated that Zenkuda demonstrated significant superiority over the sham treatment, providing a potential advancement in the management of this eye condition. Diabetic retinopathy is a leading cause of vision loss in adults and can significantly impact patients' quality of life.
The study enrolled participants with diabetic retinopathy and measured the efficacy of Zenkuda compared to placebo. Findings showed that a higher percentage of patients receiving Zenkuda experienced meaningful improvements, raising expectations for future therapeutic options. These clinical results provide a strong foundation for advancing Zenkuda's availability to individuals affected by diabetic retinopathy.
Kodiak Sciences is poised to further analyze the comprehensive data from the GLOW2 study and intends to share results in upcoming medical forums. This research represents a significant milestone in the development of treatments for diabetic retinopathy, signaling the company's commitment to addressing this serious condition with innovative solutions.
